Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy
- 2 July 2014
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 48 (9) , 1138-1144
Abstract
Background: Testosterone therapy for older men has increased substantially over the past decade. Research on the effects of testosterone therapy on cardiovascular outcomes has yielded inconsistent results. Objective: To examine the risk of myocardial infarction (MI) in a population-based cohort of older men receiving intramuscular testosterone. Method: Using a 5% national sample of Medicare beneficiaries, we identified 6355 patients treated with at least 1 injection of testosterone between January 1, 1997, and December 31, 2005. We matched this cohort to 19 065 testosterone nonusers at a 1:3 ratio based on a composite MI prognostic score. Patients were followed until December 31, 2005, or until they lost coverage from Medicare, enrolled in a health maintenance organization, experienced a MI, or died. Result: In a Cox regression analysis adjusting for demographic and clinical characteristics, receipt of testosterone therapy was not associated with an increased risk of MI (hazard ratio [HR] = 0.84; 95% CI = 0.69-1.02). In this analysis, there was an interaction between receipt of testosterone and quartile of risk of MI (P = 0.023). For men in the highest quartile of the MI prognostic score, testosterone therapy was associated with a reduced risk of MI (HR = 0.69; 95% CI = 0.53-0.92), whereas there was no difference in risk for the first (HR = 1.20; 95% CI = 0.88-1.67), second (HR = 0.94; 95% CI = 0.69-1.30), and third quartiles (HR = 0.78; 95% CI = 0.59-1.01). Conclusion: Older men who were treated with intramuscular testosterone did not appear to have an increased risk of MI. For men with high MI risk, testosterone use was modestly protective against MI.Keywords
This publication has 33 references indexed in Scilit:
- Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trialsBMC Medicine, 2013
- Endogenous testosterone levels and cardiovascular disease in healthy menHeart, 2011
- Adverse Events Associated with Testosterone AdministrationNew England Journal of Medicine, 2010
- Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-AnalysisThe Journal of Clinical Endocrinology & Metabolism, 2010
- Effects of Testosterone on Muscle Strength, Physical Function, Body Composition, and Quality of Life in Intermediate-Frail and Frail Elderly Men: A Randomized, Double-Blind, Placebo-Controlled StudyThe Journal of Clinical Endocrinology & Metabolism, 2010
- Fifty‐ two—Week Treatment With Diet and Exercise Plus Transdermal Testosterone Reverses the Metabolic Syndrome and Improves Glycemic Control in Men With Newly Diagnosed Type 2 Diabetes and Subnormal Plasma TestosteroneJournal of Andrology, 2009
- The Dark Side of Testosterone Deficiency: III. Cardiovascular DiseaseJournal of Andrology, 2009
- Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysisBritish Journal of Sports Medicine, 2006
- Androgens and the ageing maleBest Practice & Research Clinical Endocrinology & Metabolism, 2004
- Anabolic Androgenic Steroids Produce Dose-Dependent Increase in Left Ventricular Mass in Power Athletes, and this Effect is Potentiated by Concomitant Use of Growth HormoneInternational Journal of Sports Medicine, 2003